Results 271 to 280 of about 586,059 (333)

TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah   +2 more
wiley   +1 more source

Large animal renal allotransplantation; a porcine recovery model to assess delayed graft function [PDF]

open access: bronze, 2011
Christopher Ray   +15 more
openalex  

Impact of 25 Hydroxyvitamin D (25OHD) Levels in Delayed Graft Function

open access: bronze, 2012
Luis R. Leon   +11 more
openalex   +1 more source

Classification of Myelodysplastic, Myeloproliferative, and Myelodysplastic/Myeloproliferative Neoplasms: The Past, Present, and Future

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT With the recent publication of new classification systems of hematopoietic neoplasms, understanding how recognition of disease entities has occurred over time and the subsequent development of formal disease classifications is of importance. This review focuses on the early recognition of myeloid disorders, especially chronic myeloid disorders,
Daniel A. Arber, Attilio Orazi
wiley   +1 more source

An Analysis of Modifiable Factors Predictive of Delayed Graft Function in Deceased Donor Renal Transplants

open access: bronze, 2012
Matthew Cooper   +4 more
openalex   +1 more source

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem‐cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher‐risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and
Nico Gagelmann, Nicolaus Kröger
wiley   +1 more source

Topics of Interest in Women With Myeloproliferative Neoplasms

open access: yesAmerican Journal of Hematology, EarlyView.
Women with MPN: life‐cycle phases, specific risks, and influencing factors. ABSTRACT Overview Sex and gender have emerged as central modifiers of disease biology, phenotype, and clinical outcomes in myeloproliferative neoplasms (MPNs). This review will uniquely highlight issues affecting women with MPN and articulate their relevant determinants ...
Natasha Szuber   +2 more
wiley   +1 more source

A Phase II Trial of Geriatric Assessment‐Guided Selection of Treatment Intensity in Older Adults With AML

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT How to select the appropriate intensity of chemotherapy in older adults with acute myeloid leukemia (AML) remains an unanswered question. In a phase II trial of older adults ≥ 60 years with AML (n = 73), we used geriatric assessment (measures of comorbidity burden, physical and cognitive function) to determine fitness for intensive ...
Vijaya R. Bhatt   +10 more
wiley   +1 more source

Silicosarcoidosis: Histologic and Clinical Features of an Occupational Granulomatous Disease

open access: yesAmerican Journal of Industrial Medicine, EarlyView.
ABSTRACT Sarcoidosis is a multisystem inflammatory disease of unknown etiology. Growing evidence indicates that occupational exposure to respirable crystalline silica (RCS) is associated with an increased incidence of sarcoidosis. Yet a diagnosis of sarcoidosis rarely prompts investigation to identify preventable exposures.
Jeremy T. Hua   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy